Comparing effectiveness of polydeoxyribonucleotide injection and corticosteroid injection in plantar fasciitis treatment: A prospective randomized clinical study

Lee, Dong‐Oh; Yoo, Jeong Hyun; Cho, Hyung In; Cho, Soonghwan; Cho, Hyung Rae

doi:10.1016/j.fas.2019.08.005

Cited by 17 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many clinical studies have revealed that PDRN from marine organisms prevents numerous inflammation-related diseases, including bursitis, fasciitis, mucositis, and tendinopathy [ 15 , 48 , 49 , 50 , 51 , 52 , 53 ]. For instance, Om-PDRN has been found to be an effective treatment against genital lichen sclerosus (LS), supraspinatus and rotator cuff tendinopathy, and pes anserine (PA) bursitis [ 48 , 49 , 50 , 51 ].…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, the findings of this study highlight the promising potential of PDRN injections as an efficient therapeutic strategy to treat PA bursa. Two studies have also investigated the potential applicability of Ok- and Om-PDRNs as therapeutic agents for the treatment of inflammatory diseases including lateral epicondylitis and plantar fasciitis [ 52 , 53 ]. The effect of Ok-PDRN on lateral epicondylitis, the most common cause of elbow pain in adults, was evaluated on two patients experiencing right lateral elbow pain exacerbation [ 52 ].…”

Section: Resultsmentioning

confidence: 99%

“…Two studies have also investigated the potential applicability of Ok- and Om-PDRNs as therapeutic agents for the treatment of inflammatory diseases including lateral epicondylitis and plantar fasciitis [ 52 , 53 ]. The effect of Ok-PDRN on lateral epicondylitis, the most common cause of elbow pain in adults, was evaluated on two patients experiencing right lateral elbow pain exacerbation [ 52 ]. Ok-PDRN injection (1 vial, 5.625 mg/3 mL) into the common extensor tendons alleviated pain, as demonstrated by a decrease in NRS and improvement of the hypervascularity at the injected site.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering

Kim

Heo

et al. 2021

Marine Drugs

View full text Add to dashboard Cite

Polydeoxyribonucleotides (PDRNs) are a family of DNA-derived drugs with a molecular weight ranging from 50 to 1500 kDa, which are mainly extracted from the sperm cells of salmon trout or chum salmon. Many pre-clinical and clinical studies have demonstrated the wound healing and anti-inflammatory properties of PDRN, which are mediated by the activation of adenosine A2A receptor and salvage pathways, in addition to promoting osteoblast activity, collagen synthesis, and angiogenesis. In fact, PDRN is already marketed due to its therapeutic properties against various wound healing- and inflammation-related diseases. Therefore, this review assessed the most recent trends in marine organism-derived PDRN using the Google Scholar search engine. Further, we summarized the current applications and pharmacological properties of PDRN to serve as a reference for the development of novel PDRN-based technologies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering

Kim

Heo

et al. 2021

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Finally, the use of centrally acting anorectic drugs, especially those boosting the serotoninergic system, has been pursued, but the occurrence of tolerance and cardiovascular side effects has limited its therapeutic use [ 27 ]. Therefore, PDRN which is well tolerated and has shown a very good safety profile in several clinical trials [ 28 , 29 , 30 ], could represent an innovative strategy to treat obese patients.…”

Section: Discussionmentioning

confidence: 99%

Targeting Adenosine Receptor by Polydeoxyribonucleotide: An Effective Therapeutic Strategy to Induce White-to-Brown Adipose Differentiation and to Curb Obesity

et al. 2021

View full text Add to dashboard Cite

Obesity is a worldwide chronic metabolic disease characterized by an abnormal fat accumulation and represents one of the main risk factors for several diseases. White adipose tissue is the primary site for energy storage in the form of triglycerides, whereas brown adipose tissue does not store energy-providing lipids but rather dissipates it by producing heat. White-to-brown adipocyte trans-differentiation could represent a new target of anti-obesity strategies and result in fat reduction. Previous studies indicated that adenosine receptor activation induces trans-differentiation of white adipocytes to brown adipocytes. The aim of this study was to evaluate the effects of polydeoxyribonucleotide (PDRN), an A2Ar receptor agonist, in an in vitro model of browning. Mouse 3T3-L1 pre-adipocytes were differentiated in mature adipocytes with specific culture media and then treated with PDRN (10 µg/mL), PDRN + ZM241385 (1 µM), CGS21680 (1 µM) and CGS + ZM241385 for 24 h. Cell viability was studied by MTT assay, and browning induction was evaluated by Oil Red O staining and by RT-qPCR to study gene expression of browning markers. PDRN, as well as CGS21680, reduced the accumulation of lipids, cell volume and lipid droplet size; increased the expression of UCP1, PRDM16 and DIO2, considered as browning markers; and reduced the expression of FASn and FABP4, considered as whitening markers. In addition, PDRN decreased leptin expression and enhanced adiponectin mRNA levels. All these effects were abrogated when PDRN was co-incubated with the A2Ar antagonist ZM241385. In conclusion, these results suggest that PDRN is able to induce the white-to-brown adipose differentiation through A2Ar stimulation. Since PDRN is a safe drug already available in the market for other therapeutic indications, its “anti-obesity” potential warrants investigation in a clinical scenario.

show abstract

“…The MOXFQ has been used as an outcome measure in clinical trials of various injection therapies for neuroma and plantar heel pain , in clinical trials of bracing for ankle fracture , and in clinical trials of surgery for hallux valgus and ankle osteoarthritis .…”

Section: Manchester‐oxford Foot Questionnairementioning

confidence: 99%

Measures of Foot Pain, Foot Function, and General Foot Health

Whittaker

Munteanu

Roddy

et al. 2020

Arthritis Care & Research

View full text Add to dashboard Cite

Comparing effectiveness of polydeoxyribonucleotide injection and corticosteroid injection in plantar fasciitis treatment: A prospective randomized clinical study

Cited by 17 publications

References 16 publications

Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering

Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering

Targeting Adenosine Receptor by Polydeoxyribonucleotide: An Effective Therapeutic Strategy to Induce White-to-Brown Adipose Differentiation and to Curb Obesity

Measures of Foot Pain, Foot Function, and General Foot Health

Contact Info

Product

Resources

About